Literature DB >> 19506527

Management of antihypertensive drugs in three European countries.

Federica Nicotra1, Björn Wettermark, Miriam C Sturkenboom, Andrea Parodi, Rino Bellocco, Anders Ekbom, Luca Merlino, Andrejs Leimanis, Giuseppe Mancia, Michael Fored, Giovanni Corrao.   

Abstract

OBJECTIVES: To compare rates of treatment discontinuation of and changes in initial antihypertensive drug therapy in the natural setting of treatment dispensation of Italy, Sweden and the Netherlands.
METHODS: The cohorts included all the 23 715 (Italy), 20 289 (Sweden), and 5801 (the Netherlands) patients aged 40-70 years who received their first antihypertensive drug prescription from July 1, 2006 to September 30, 2006. Discontinuation was assumed if no antihypertensive drug was issued within 90 days following the end of the latest antihypertensive dispensation. Addition or replacement of the initial medication during the 90-day interval were defined as treatment combination or treatment switching.
RESULTS: At 9 months after treatment initiation, the discontinuation rate of any antihypertensive drug was 24%. Compared with Italian patients, the discontinuation rate was significantly lower in Swedish [hazard ratios: 0.52, 95% confidence interval (CI): 0.50-0.54] and Dutch patients (hazard ratio: 0.79, 95% CI: 0.75-0.84). Almost 21 and 16% of patients who started on monotherapy respectively combined with and switched to another antihypertensive drug. Compared with Italian patients, the adjusted hazard rate of combining was lower in Swedish patients (hazard ratio: 0.83, 95% CI: 0.79-0.87). The hazard rate of switching was lower in Swedish and Dutch patients than in Italians (hazard ratios: 0.83, 95% CI: 0.79-0.88 and hazard ratio: 0.77, 95% CI: 0.71-0.84 respectively).
CONCLUSION: Management of hypertension is unsatisfactory worldwide due to a very high rate of treatment discontinuation or insufficient use of proper treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506527     DOI: 10.1097/HJH.0b013e32832d4692

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Substantial blood pressure reduction with renal denervation in a drug-naïve patient intolerant to antihypertensive pharmacotherapy: a case report.

Authors:  J Xu; A Walton; D Hering; Y Sata; M P Schlaich
Journal:  J Hum Hypertens       Date:  2013-11-21       Impact factor: 3.012

2.  Persistence to antihypertensive drug treatment in Swedish primary healthcare.

Authors:  Miriam Qvarnström; Thomas Kahan; Helle Kieler; Lena Brandt; Jan Hasselström; Kristina Bengtsson Boström; Karin Manhem; Per Hjerpe; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.953

3.  Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD).

Authors:  Miriam Qvarnström; Thomas Kahan; Helle Kieler; Lena Brandt; Jan Hasselström; Kristina Bengtsson Boström; Karin Manhem; Per Hjerpe; Björn Wettermark
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

4.  Switching of antihypertensive drugs at Tertiary Care Government Hospital, Hyderabad, India: A cross-sectional retrospective investigation.

Authors:  Varsha Varakantham; Ashok Kumar Kurakula Sailoo; Venkaiah Kodali; Dinesh Kumar Bharatraj
Journal:  Indian J Pharmacol       Date:  2017 Nov-Dec       Impact factor: 1.200

5.  Trends of blood pressure levels and management in Västerbotten County, Sweden, during 1990-2010.

Authors:  Nawi Ng; Bo Carlberg; Lars Weinehall; Margareta Norberg
Journal:  Glob Health Action       Date:  2012-07-30       Impact factor: 2.640

6.  Initial antihypertensive prescription and switching: a 5 year cohort study from 250,851 patients.

Authors:  Martin C S Wong; Wilson W S Tam; Clement S K Cheung; Ellen L H Tong; Antonio C H Sek; George John; N T Cheung; Bryan P Y Yan; C M Yu; Stephen Leeder; Sian Griffiths
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.